Sells the only FDA-approved drug for a rare childhood liver condition that causes severe itching.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleMarket cap is above the global median
Sells the only FDA-approved drug for a rare childhood liver condition that causes severe itching.
What this company is and how it runs — written from structure, not news.
Mirum Pharmaceuticals sells maralixibat, a drug that blocks the protein in the gut responsible for reabsorbing bile acids, which relieves the severe itching that builds up in children with Alagille syndrome when those acids accumulate in the body. Because the patients are young children who cannot swallow tablets, every dose must be produced as a calibrated oral liquid through manufacturing lines built specifically for that formulation — lines that took years to validate and exist only to serve this narrow patient group. That narrow group is also what makes the business depend entirely on FDA orphan drug exclusivity: the population of Alagille syndrome patients is small enough that a single generic competitor entering the market would destroy pricing before manufacturing costs are recovered, so the commercial logic only holds while the orphan designation — tied specifically to maralixibat in this exact indication — remains intact. The company can grow by winning approval for additional rare cholestatic conditions using the same drug and the same manufacturing lines, but the total number of children in the world with these diseases is fixed by biology, so the ceiling on revenue is set not by how well the company executes but by how many patients exist to treat.
How does this company make money?
The company sells maralixibat in per-unit amounts through specialty pharmacy channels. The price is protected by FDA orphan drug exclusivity, which legally prevents generics from undercutting it. Payment comes primarily from pediatric Medicaid programs and from private insurance plans that have rare disease coverage policies.
What makes this company hard to replace?
Doctors who prescribe maralixibat must complete a lengthy FDA-required process called a Risk Evaluation and Mitigation Strategy before they can write a prescription, which creates real procedural work to stop and start again with a different drug. Children on maralixibat need their dose adjusted gradually over several months to bring bile acid levels down safely, so stopping treatment mid-course is clinically risky. On top of that, specialty pharmacies build specific prior authorization and insurance coordination processes around each orphan drug, and those processes would have to be rebuilt from scratch if a prescriber switched to something else.
What limits this company?
The number of children who have Alagille syndrome and the other rare liver diseases maralixibat could treat is biologically fixed. No amount of money, extra sales staff, or bigger factories can create more patients. Every new condition the drug tries to treat requires a separate clinical trial drawing from the same small pool of children who can be found at pediatric hepatology centers around the world.
What does this company depend on?
The company cannot operate without five named inputs: FDA orphan drug exclusivity for maralixibat, manufacturing facilities that can produce a stable pediatric oral liquid formulation of a bile acid transporter inhibitor, clinical trial sites with access to Alagille syndrome patients, specialty pharmacy distribution networks that serve rare disease patients, and European Medicines Agency marketing authorization to sell outside the United States.
Who depends on this company?
Pediatric hepatology centers would lose their only FDA-approved treatment for cholestatic pruritus in Alagille syndrome and would have nothing comparable to prescribe. Specialty pharmacies that serve rare disease patients would lose a key orphan drug from their drug lists. Parents of children with Alagille syndrome would be left managing symptoms with off-label treatments that do not target the underlying bile acid transport problem the way maralixibat does.
How does this company scale?
Winning regulatory approval for additional cholestatic conditions would let the company use the same maralixibat mechanism and the same manufacturing lines across multiple orphan indications without rebuilding from scratch. But clinical development cannot grow past the total number of children in the world who have these specific rare liver diseases, so no matter how efficiently the company runs, the ceiling on the number of patients — and therefore the ceiling on revenue — is set by biology, not by operations.
What external forces can significantly affect this company?
Changes to Medicare and Medicaid reimbursement rules could reduce or eliminate coverage for high-cost orphan drugs in pediatric patients, which are currently a primary payer for maralixibat. European Union orphan drug pricing regulations could cap how much the company can charge in international markets. Expansions of newborn screening programs could shift when Alagille syndrome is diagnosed, which would change how early and how often treatment begins.
Where is this company structurally vulnerable?
If the FDA revokes or successfully challenges maralixibat's orphan drug exclusivity — whether through a regulatory review or a legal challenge — generic versions of ileal bile acid transporter inhibitors could enter the market. The patient population is too small to support branded pricing against a generic, and because the exclusivity is tied so specifically to this drug and this indication, there is no neighboring protected market to fall back on.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
Is this company growing?
R&D expense is a large share of revenue; diluted share count has grown on a 6-year basis; stock-based compensation is a large share of trailing revenue.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph